We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Persistent Urinary Albumin May Indicate Risk for Cognitive Decline in Type II Diabetics

By LabMedica International staff writers
Posted on 10 Sep 2013
The chronic presence of albumin in the urine (albuminuria) of individuals with type II diabetes has been linked to a gradual decline in their ability to process information (i.e., cognitive decline).

Investigators at Kaiser Permanente of Georgia/Emory School of Medicine (Duluth, GA, USA) determined the level of albumin in urine samples obtained from participants in the Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study. This study comprised 2,977 individuals with mean age 62.5 years who had been recruited from August 2003 to December 2005 and then followed through June 2009. The purpose of the study was to examine the association of intensive versus standard glucose control on cognitive function. Participants underwent three neuropsychologic tests at baseline, 20 months, and 40 months. Tests included information processing speed, verbal memory, and executive function. Urine albumin measurements were carried out in parallel with the memory tests.

Results revealed that participants with albuminuria at baseline and follow-up (persistent albuminuria) and participants with albuminuria at follow-up but none at baseline (progressive albuminuria) had greater percentage declines on information processing speed than participants without albuminuria at baseline and at follow-up (no albuminuria). Persistent albuminuria and progressive albuminuria were associated with about a 5% decline in information processing speed scores but not with verbal memory or executive function performance.

Senior author Dr. Joshua Barzilay, an endocrinologist at Kaiser Permanente, said, “Our finding was a subtle change in cognition; however, were this decline to continue over 10 to 15 years it could translate into noticeable cognitive decline by the age of 75 to 80 years, when cognitive impairment generally becomes clinically evident. Given how common albuminuria and diabetes are in the older population, these findings have a great deal of importance from a population point of view. Moreover, albuminuria is also common among older people with hypertension without diabetes.”

The study was published in the August 29, 2013, online edition of the Clinical Journal of the American Society of Nephrology.

Related Links:

Kaiser Permanente of Georgia/Emory School of Medicine



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test

Latest Clinical Chem. News

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
10 Sep 2013  |   Clinical Chem.

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
10 Sep 2013  |   Clinical Chem.

Low-Cost Portable Screening Test to Transform Kidney Disease Detection
10 Sep 2013  |   Clinical Chem.